2023
A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
Ritch E, Herberts C, Warner E, Ng S, Kwan E, Bacon J, Bernales C, Schönlau E, Fonseca N, Giri V, Maurice-Dror C, Vandekerkhove G, Jones S, Chi K, Wyatt A. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. Npj Precision Oncology 2023, 7: 27. PMID: 36914848, PMCID: PMC10011564, DOI: 10.1038/s41698-023-00366-z.Peer-Reviewed Original ResearchMetastatic prostate cancerDDR gene alterationsProstate cancerGene alterationsDDR deficiencyOngoing clinical trialsPlasma cell-free DNADNA damage repair defectsLiquid biopsy specimensMismatch repair deficiencyLeukocyte DNA samplesBladder cancer samplesCell-free DNABiopsy specimensBladder cancerClinical trialsTreatment benefitMetastatic prostate
2022
Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study.
Giri V, Gross L, Cheng H, Russo J, Paller C, Johnson J, Weg E, Loeb S. Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study. Journal Of Clinical Oncology 2022, 40: 184-184. DOI: 10.1200/jco.2022.40.6_suppl.184.Peer-Reviewed Original ResearchMetastatic prostate cancerProstate cancerGermline testingGenetic counselingRisk of PCaEarly-stage prostate cancerBaseline surveyHigh-risk diseaseStandard of careCancer genetic testingCancer genetics knowledgeMedical oncologistsMedical oncologyClinical trial managementClinical trialsNurse practitionersCancer managementAcademic centersFavorable responseCase discussionRadiation oncologistsPCa screeningKnowledge scoreGenetic testingPractice settingsPrevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study.
Giri V, Gross L, Russo J, Shimada A, McNair C, Kelly W, Gomella L. Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study. Journal Of Clinical Oncology 2022, 40: 188-188. DOI: 10.1200/jco.2022.40.6_suppl.188.Peer-Reviewed Original ResearchProstate cancerPrevalence of FAGermline testingEMPOWER studyMultigene testingMutation carriersMutation prevalencePopulation prevalenceExact testLimited prevalence dataGene mutationsLikely pathogenic mutationsFisher's exact testCancer risk genesClinical characteristicsGleason scoreMean ageClinical trialsPCa diagnosisFA genesFas gene mutationPrevalence ratesCancer managementPCa biologyFA pathway genes
2018
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.Peer-Reviewed Original ResearchGermline genetic testingProstate cancerGenetic testingAdvanced diseaseClinical trialsTreatment selectionProstate Cancer Clinical Trials ConsortiumClinical trial eligibility determinationCascade testingClinical Trials ConsortiumTherapeutic clinical trialsGenetic counselingClinical trial purposesTumor genomic profilingPost-test genetic counselingCancer risk assessmentDNA damage repair genesAppropriate genetic counselingTreatment response predictionWorking GroupClinical benefitPrompt testingCancer screeningGenetic testing practicesTreatment decisions